It would stand to reason that at a time of stock market retraction and a global recessionary environment, the Biotech sector would face a funding crunch. In both public and private markets however, money is flowing into biotech discusses David Mardle a UK-based partner in the technology and life sciences practices of Goodwin. Read the article in Scrip here.